Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) is a biotechnology company that focuses on developing small molecule drugs for viral infections and liver diseases. The company is known for its research and development efforts in creating treatments for hepatitis C, respiratory syncytial virus, and non-alcoholic steatohepatitis. Enanta operates in a competitive landscape alongside other biotech firms like Xencor, PTC Therapeutics, Agios Pharmaceuticals, and MacroGenics.
In evaluating Enanta's financial performance, the Return on Invested Capital (ROIC) is a critical metric. Enanta's ROIC is -22.45%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 6.37%. This negative ROIC indicates that Enanta is not generating enough returns to cover its cost of capital, which is a concern for investors.
Comparing Enanta to its peers, Xencor, Inc. (XNCR) also shows a negative ROIC of -14.41% against a WACC of 10.03%, resulting in a ROIC to WACC ratio of -1.44. This suggests that Xencor, like Enanta, is struggling to generate returns above its cost of capital. However, Xencor's situation is slightly better than Enanta's, given its less negative ROIC to WACC ratio.
On the other hand, PTC Therapeutics, Inc. (PTCT) stands out with a positive ROIC of 37.39% and a WACC of 7.81%, leading to a ROIC to WACC ratio of 4.79. This indicates that PTC is efficiently using its capital to generate returns well above its cost of capital, making it the most efficient among its peers.
Agios Pharmaceuticals, Inc. (AGIO) and MacroGenics, Inc. (MGNX) both exhibit negative ROICs of -38.18% and -49.08%, respectively, with ROIC to WACC ratios of -4.91 and -5.57. These figures highlight that these companies, like Enanta, are not covering their cost of capital, which could be a red flag for potential investors.
